Trial Information
Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients
Inclusion Criteria:
- Hodgkin Lymphoma, intermediate or advanced stage
- Age >60 and <75 years
- ECOG 2 or better
- No major organ dysfunction
- Ability to take aspirin or LMW Heparin
Exclusion Criteria:
- HL as composite lymphoma
- Prior use of lenalidomide
- Prior use of chemo- or radiotherapy
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Dose limiting toxicities (DLT)
Safety Issue:
Yes
Principal Investigator
Andreas Engert, Prof.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Cologne
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
AVD-Rev
NCT ID:
NCT01056679
Start Date:
April 2010
Completion Date:
April 2014
Related Keywords:
- Hodgkin Lymphoma
- Hodgkin Disease
- Lymphoma